Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-28T08:09:28.494Z Has data issue: false hasContentIssue false
  • English
  • Français

The Preclinical Profile of the New Antipsychotic, Ziprasidone

Published online by Cambridge University Press:  16 April 2020

J.E. Bradbury ,
S.H. Zorn ,
K.D. Wilner ,
J.J. Miceli ,
D. Wong ,
C.J. Bench  and
R.S.J. Frackowiak
J.E. Bradbury
Affiliation:
Pfizer Central Research, Sandwich, Kent, CT13 9NJ, UK
S.H. Zorn
Affiliation:
Pfizer Central Research, Groton, CT06340USA
K.D. Wilner
Affiliation:
Pfizer Central Research, Groton, CT06340USA
J.J. Miceli
Affiliation:
Pfizer Central Research, Groton, CT06340USA
D. Wong
Affiliation:
Johns Hopkins Medical Institutions, Baltimore, MD21287, USA
C.J. Bench
Affiliation:
Hammersmith Hospital, London, W12 0HS, UK Royal Free Hospital and School of Medicine, London, NW3 2XJ, UK
R.S.J. Frackowiak
Affiliation:
Royal Free Hospital and School of Medicine, London, NW3 2XJ, UK

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Poster Presentations
Information
European Psychiatry , Volume 11 , Issue S4: European psychiatry: a force for the future - 8th Congress of Association of European Psychiatrists and Annual Meeting of the Royal College of Psychiatrists , 1996 , pp. 404s - 405s
Copyright
Copyright © Elsevier Paris 1996
Submit a response

Comments

No Comments have been published for this article.